List of Radiopharmaceuticals/Radiotherapies Companies in Netherlands - 2

Search through the full list with powerful filtering options

Want this in Excel? Get Quote Now

Company

About

Cortalix BV

Cortalix BV

Zernikelaan 8, Groningen, 9747 AW, NL

Cortalix is a clinical-stage biopharmaceutical company developing imaging diagnostics and targeted radiotherapeutics based on its proprietary single domain antibodies (nanobodies) platform. Cortalix developed a pipeline of radiopharmaceuticals that target fibrogenesis-related membrane receptors and proteins that appear in early stage fibrotic diseases such as in pulmonary fibrosis, cardiac fibrosis, hepatic fibrosis and several solid cancers with fibrotic stroma, including colon cancer and pancreatic cancer. The Cortalix technology platform is based on the screening and selection of single domain antibodies for myofibroblast-specific membrane proteins and receptors including PDGFRA (CD140a), PDGFRB (CD140b), EGFR, IGF-2R (CD222) and FAP. Our nanobodies do contain a functional group that can chelate a radionuclide suitable for nuclear imaging. Eventually the platform allows for a theranostic approach in cancer using the same single domain antibody for patient identification, targeted therapy and disease monitoring (a combined diagnostic and therapeutic in 1 molecule). Cortalix wants to share its single domain antibodies platform, the selection of new candidate molecules from it and, if appropriate, the development of new radiopharmaceuticals with others and offers this knowledge as a service, whether or not under license.

Tagworks Pharmaceuticals

Tagworks Pharmaceuticals

Nijmegen, Netherlands

Tagworks Pharmaceuticals is a precision oncology company using our proprietary Click-to-Release treatment platform to develop a new standard of care for patients suffering from solid tumors by targeting clinically validated tumor markers that so far have remained out of reach of current therapies. Our lead program, TGW101, is an antibody-drug conjugate (ADC) targeting TAG72, a non-internalizing protein found on the surface of many solid tumor cells. We are developing a pipeline of novel cancer treatments leveraging our Click-to-Release technology in a range of therapeutic modalities, including ADCs and targeted radionuclide therapies. We are headquartered in the Netherlands with operations in the U.S. For more information, visit us at www.tagworkspharma.com.